Literature DB >> 6279995

Chemotherapy for salivary gland cancer.

J Y Suen, M E Johns.   

Abstract

Salivary gland cancers are usually treated with surgery and irradiation; however, some of the aggressive salivary gland cancers recur or metastasize and are not amendable to treatment with further surgery or irradiation. Little is known about chemotherapy for these palliative situations because of the relatively scarcity of these cancers. The data in the literature has provided little clinical information because all salivary gland cancers are usually lumped together and/or multiple different drug combination are used. In an effort to arrive at a rational basis for recommending specific drug regimens for specific histologic types of salivary gland cancers, a two-part study was undertaken to determine which chemotherapy drugs seem to be effective or ineffective. One part was a literature review, and the second part was a survey of numerous institutions' experiences, including our own. A total of 85 cases of salivary gland cancers treated with chemotherapy were felt to be evaluable for this study. The overall response rate (complete and partial) was 42%. Although disease responded whether it was local, regional, or distant disease, there was a higher response rate in local-regional disease compared to distant metastases. Salivary gland cancers are definitely sensitive to chemotherapy drugs. This study reveals which drugs seem to be effective and provides some rational basis for future chemotherapy trials for salivary gland cancers.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6279995     DOI: 10.1288/00005537-198203000-00003

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  10 in total

1.  Adenoid cystic carcinoma of the skull base.

Authors:  P R Issing; I Hemmanouil; T Stöver; H G Kempf; L Wilkens; R Heermann; T Lenarz
Journal:  Skull Base Surg       Date:  1999

2.  Clinical and microdissection genotyping analyses of the effect of intra-arterial cytoreductive chemotherapy in the treatment of lacrimal gland adenoid cystic carcinoma.

Authors:  David T Tse
Journal:  Trans Am Ophthalmol Soc       Date:  2005

Review 3.  Chemotherapeutic management of head and neck cancer.

Authors:  M Al-Sarraf
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

4.  Current role of chemotherapy in exclusive and integrated treatment of malignant tumours of salivary glands.

Authors:  G Cortesina; M Airoldi; F Palonta
Journal:  Acta Otorhinolaryngol Ital       Date:  2005-06       Impact factor: 2.124

5.  Image-guided volumetric modulated arc therapy (IG-VMAT) for unresectable ACC of the trachea: a feasible curative option.

Authors:  Rahul Lal Chowdhary; Kundan Singh Chufal; Anjali Kakria Pahuja; Manindra Bhushan; Rajpal Singh; Irfan Ahmad
Journal:  BMJ Case Rep       Date:  2019-03-21

6.  [Malignant tumors of the salivary glands: early diagnosis, follow-up and therapy].

Authors:  R Chilla; R Casjens; U Eysholdt; M Droese
Journal:  Arch Otorhinolaryngol       Date:  1983-04

Review 7.  Chemotherapy for cranial base tumors.

Authors:  H E Jacob
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

8.  Methotrexate and 5-fluorouracil in the treatment of squamous and other carcinomas of the head and neck.

Authors:  D J Stewart; J A Maroun; C Cripps; V Young; G Laframboise; J Gerin-Lajoie
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 9.  Systemic therapy in the management of metastatic or advanced salivary gland cancers.

Authors:  Aymen Lagha; Nesrine Chraiet; Mouna Ayadi; Sarra Krimi; Bassem Allani; Hela Rifi; Henda Raies; Amel Mezlini
Journal:  Head Neck Oncol       Date:  2012-05-04

Review 10.  Activity of chemotherapy in the palliative treatment of salivary gland tumors: review of the literature.

Authors:  Sophia Rizk; Annie Robert; Annick Vandenhooft; Mario Airoldi; Gabriela Kornek; Jean-Pascal Machiels
Journal:  Eur Arch Otorhinolaryngol       Date:  2007-04-06       Impact factor: 3.236

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.